7,142,857 SHARES CHECKPOINT THERAPEUTICS, INC. COMMON STOCK UNDERWRITING AGREEMENTUnderwriting Agreement • September 21st, 2020 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule V hereto (the “Underwriters”), for whom H.C. Wainwright & Co., LLC is acting as representative (the “Representative”), an aggregate of 7,142,857 authorized but unissued shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), and, at the election of the Underwriters, upon the terms and conditions stated herein, up to 1,071,428 additional shares (the “Additional Shares”) of Common Stock solely to cover over-allotments, if any (the Firm Shares and the Additional Shares that the Underwriters elect to purchase pursuant to Section 3 hereof being collectively called the “Securities”).
